Rhumbline Advisers Beyond Spring Inc. Transaction History

Rhumbline Advisers

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$1.13 - $2.66 $22,702 - $53,442	-20,091 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$1.68 - $5.01 $7,487 - $22,329	4,457 Added 28.51%	20,091 $44,000
Q4 2021 Feb 10, 2022	SELL	$4.02 - $16.84 $2,637 - $11,047	-656 Reduced 4.03%	15,634 $71,000
Q3 2021 Nov 12, 2021	BUY	$9.26 - $31.31 $12,454 - $42,111	1,345 Added 9.0%	16,290 $257,000
Q2 2021 Aug 05, 2021	BUY	$9.37 - $12.12 $20,164 - $26,082	2,152 Added 16.82%	14,945 $156,000
Q1 2021 May 06, 2021	BUY	$10.61 - $15.77 $2,440 - $3,627	230 Added 1.83%	12,793 $142,000
Q4 2020 Feb 10, 2021	BUY	$10.21 - $17.31 $16,244 - $27,540	1,591 Added 14.5%	12,563 $153,000
Q3 2020 Nov 12, 2020	SELL	$9.99 - $16.13 $24,465 - $39,502	-2,449 Reduced 18.25%	10,972 $146,000
Q2 2020 Aug 13, 2020	BUY	$11.21 - $18.15 $32,015 - $51,836	2,856 Added 27.03%	13,421 $202,000
Q1 2020 May 06, 2020	BUY	$9.68 - $18.47 $102,269 - $195,135	10,565 New	10,565 $135,000

5.55M

26K

2.4K

Ticker BYSI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,928,900
Market Cap $68.1M
Description
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.